UPDATE 1-AstraZeneca's Imfinzi gets speedy FDA review for small cell lung cancer

UPDATE 1-AstraZeneca's Imfinzi gets speedy FDA review for small cell lung cancerBritish drugmaker AstraZeneca Plc said on Friday its immunotherapy cancer treatment Imfinzi has been granted a speedy review by the U.S. medicines watchdog for the treatment of a particularly aggressive type of lung cancer. The company said the U.S. Food and Drug Administration (FDA) accepted its supplemental application and granted priority review to Imfinzi for the treatment of previously untreated late-stage small cell lung cancer (SCLC). The FDA decision is a boost for the treatment as it competes against similar medicines from rivals Merck and Roche , and follows data in September which showed Imfinzi prolonged survival in SCLC patients when used with chemotherapy.



Yahoo Finance

You may also like...